Therapeutic transfer of DNA encoding adenoviral E1A

Recent Patents on Anti-Cancer Drug Discovery

Volumn 2, Issue 1, 2007, Pages 1-10

  Deissler, Helmut ^a   Opalka, Bertram ^b  

^a UNIVERSITY OF ULM MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

Author keywords

Adenovirus; Apoptosis; Breast cancer; E1A; Gene therapy; Head and neck cancer; HER 2 neu; Ovarian cancer

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; CYTOTOXIC AGENT; DOUBLE STRANDED DNA; DOXORUBICIN; E1A PROTEIN; ETOPOSIDE; GEMCITABINE; LIPOSOME; PACLITAXEL; PROTAMINE; RETROVIRUS VECTOR;

ABDOMINAL PAIN; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER GENE THERAPY; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; DNA SYNTHESIS; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC CODE; HEAD AND NECK CANCER; HUMAN; MALIGNANT TRANSFORMATION; MULTIPLE CYCLE TREATMENT; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ONCOGENE; ONCOGENE NEU; OPTIMAL DRUG DOSE; OVARY CANCER; PATENT; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; TRANSCRIPTION REGULATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS GENE; VIRUS GENOME; VIRUS REPLICATION; VIRUS STRAIN;

EID: 34248143074     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489207779561471     Document Type: Review

References (75)

1. Mymryk JS. Tumour suppressive properties of the adenovirus 5 E1A oncogene. Oncogene 1996; 13: 1581-89.
2. Frisch SM, Mymryk JS. Adenovirus-5 E1A: paradox and paradigm. Nat Rev Mol Cell Biol 2002; 3: 441-52.
3. Berk AJ. Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 2005; 24: 7673-85.
4. Cook JL, Routes JM. Adenovirus E1A gene-induced tumor cell rejection through cellular sensitization to immune and nonimmune apoptotic injuries. Front Biosci 2005; 10: 1396-414.
5. Kaplan JM. Adenovirus-based cancer gene therapy. Curr Gene Ther 2005; 5: 595-605.
6. Mathis JM, Stoff-Khalili MA, Curiel DT. Oncolytic adeno-viruses - selective retargeting to tumor cells. Oncogene 2005; 24: 7775-91.
7. Rasti M, Grand RJ, Yousef AF, et al. Roles for APIS and the 20S proteasome in adenovirus E1A-dependent transcription. EMBO J 2006; 25: 2710-22.
8. Ulfendahl PJ, Linder S, Kreivi JP, et al. A novel adenovirus-2 E1A mRNA encoding a protein with transcription activation properties. EMBO J 1987; 6: 2037-44.
9. Brockmann D, Esche H. The multifunctional role of E1A in the transcriptional regulation of CREB/CBP-dependent target genes. Curr Top Microbiol Immunol 2003; 272: 97-129.
10. Turnell AS, Grand RJ, Gorbea C, et al. Regulation of the 26S proteasome by adenovirus E1A. EMBO J 2000; 19: 4759-73.
11. Gallimore PH, Turnell AS. Adenovirus E1A: remodelling the host cell, a life or death experience. Oncogene 2001; 20: 7824-35.
12. Dumont DJ, Marcellus RC, Bayley ST, Branton PE. Role of phosphorylation near the amino terminus of adenovirus type 5 early region 1A proteins. J Gen Virol 1993; 74 (Pt 4): 583-95.
13. Whalen SG, Marcellus RC, Barbeau D, Branton PE. Importance of the Ser-132 phosphorylation site in cell transformation and apoptosis induced by the adenovirus type 5 E1A protein. J Virol 1996; 70: 5373-83.
14. Zhang Q, Yao H, Vo N, Goodman RH. Acetylation of adenovirus E1A regulates binding of the transcriptional corepressor CtBP. Proc Natl Acad Sci USA 2000; 97: 14323-8.
15. Culp JS, Webster LC, Friedman DJ, et al. The 289-amino acid E1A protein of adenovirus binds zinc in a region that is important for trans-activation. Proc Natl Acad Sci USA 1988; 85: 6450-4.
16. Rasti M, Grand RJ, Mymryk JS, Gallimore PH, Turnell AS. Recruitment of CBP/p300, TATA-binding protein, and S8 to distinct regions at the N terminus of adenovirus E1A. J Virol 2005; 79: 5594-605.
17. Lipinski KS, Kroner-Lux G, Esche H, Brockmann D. The E1AN terminus (aa 1-29) of the highly oncogenic adenovirus type 12 harbours a trans-activation function not detectable in the non-oncogenic serotype 2. J Gen Virol 1997; 78 (Pt 2): 413-21.
18. Loewenstein PM, Arackal S, Green M. Mutational and functional analysis of an essential subdomain of the adenovirus E1A N-terminal transcription repression domain. Virology 2006; 351: 312-21.
19. Strom AC, Ohlsson P, Akusjarvi G. AR1 is an integral part of the adenovirus type 2 E1A-CR3 transactivation domain. J Virol 1998; 72: 5978-83.
20. Velcich A, Ziff E. Adenovirus Ela proteins repress transcription from the SV40 early promoter. Cell 1985; 40: 705-16.
21. Hen R, Borrelli E, Chambon P. Repression of the immunoglobulin heavy chain enhancer by the adenovirus-2 E1A products. Science 1985; 230: 1391-94.
22. Frisch SM. Tumor suppression activity of adenovirus E1a protein: anoikis and the epithelial phenotype. Adv Cancer Res 2001; 80: 39-49.
23. White E. Regulation of the cell cycle and apoptosis by the oncogenes of adenovirus. Oncogene 2001; 20: 7836-46.
24. Ben Israel H, Kleinberger T. Adenovirus and cell cycle control. Front Biosci 2002; 7: d1369-d1395.
25. Sang N, Caro J, Giordano A. Adenoviral E1A: everlasting tool, versatile applications, continuous contributions and new hypotheses. Front Biosci 2002; 7: d407-d413.
26. Avvakumov N, Kajon AE, Hoeben RC, Mymryk JS. Comprehensive sequence analysis of the E1A proteins of human and simian adenoviruses. Virology 2004; 329:477-92.
27. Schaeper U, Boyd JM, Verma S, Uhlmann E, Subramanian T, Chinnadurai G. Molecular cloning and characterization of a cellular phosphoprotein that interacts with a conserved C-terminal domain of adenovirus E1A involved in negative modulation of oncogenic transformation. Proc Natl Acad Sci USA 1995; 92: 10467-71.
28. Cuilliere-Dartigues P, El Bchiri J, Krimi A, et al. TCF-4 isoforms absent in TCF-4 mutated MSI-H colorectal cancer cells colocalize with nuclear CtBP and repress TCF-4-mediated transcription. Oncogene 2006; 25: 4441-48.
29. Frisch SM. Antioncogenic effect of adenovirus E1A in human tumor cells. Proc Natl Acad Sci USA 1991; 88: 9077-81.
30. Frisch SM. E1a induces the expression of epithelial characteristics. J Cell Biol 1994; 127: 1085-96.
31. Yu D, Suen TC, Yan DH, Chang LS, Hung MC. Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc Natl Acad Sci USA 1990; 87: 4499-503.
32. Yan DH, Chang LS, Hung MC. Repressed expression of the HER-2/c-erbB-2 proto-oncogene by the adenovirus E1a gene products. Oncogene 1991; 6: 343-45.
33. Zhang Y, Yu D, Xia W, Hung MC. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model. Oncogene 1995; 10: 1947-54.
34. Yu D, Matin A, Xia W, Sorgi F, Huang L, Hung MC. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene 1995; 11: 1383-8.
35. Frisch SM, Dolter KE. Adenovirus E1a-mediated tumor suppression by a c-erbB-2/neu-independent mechanism. Cancer Res 1995; 55: 5551-55.
36. Sanchcz-Prieto R, Quintanilla M, Cano A, et al. Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene. Oncogene 1996; 13: 1083-92.
37. Brader KR, Wolf JK, Hung MC, et al. Adenovirus E1A expression enhances the sensitivity of an ovarian cancer cell line to multiple cytotoxic agents through an apoptotic mechanism. Clin Cancer Res 1997; 3: 2017-24.
38. Ueno NT, Yu D, Hung MC. Chemosensitization of HER-2/neuoverexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene 1997; 15: 953-60.
39. Deng J, Xia W, Hung MC. Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo. Oncogene 1998; 17: 2167-75.
40. Zhou Z, Jia SF, Hung MC, Kleinerman ES. E1A sensitizes HER2/ neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs. Cancer Res 2001; 61: 3394-98.
41. Hubberstey AV, Pavliv M, Parks RJ. Cancer therapy utilizing an adenoviral vector expressing only E1A. Cancer Gene Ther 2002; 9: 321-29.
42. Cook JL, Miura TA, Ikle DN, Lewis AM Jr, Routes JM. E1A oncogene-induced sensitization of human tumor cells to innate immune defenses and chemotherapy-induced apoptosis in vitro and in vivo. Cancer Res 2003; 63: 3435-43.
43. Lee WP, Tai DI, Tsai SL, et al. Adenovirus type 5 E1A sensitizes hepatocellular carcinoma cells to gemcitabine. Cancer Res 2003; 63: 6229-36.
44. Liao Y, Hung MC. Regulation of the activity of p38 mitogen-activated protein kinase by Akt in cancer and adenoviral protein E1A-mediated sensitization to apoptosis. Mol Cell Biol 2003; 23: 6836-48.
45. Flinterman M, Gaken J, Farzaneh F, Tavassoli M. E1A-mediated suppression of EGFR expression and induction of apoptosis in head and neck squamous carcinoma cell lines. Oncogene 2003; 22: 1965-77.
46. Shao R, Xia W, Hung MC. Inhibition of angiogenesis and induction of apoptosis are involved in E1A-mediated bystander effect and tumor suppression. Cancer Res 2000; 60: 3123-26.
47. Deng J, Kloosterbooer F, Xia W, Hung MC. The NH(2)-terminal and conserved region 2 domains of adenovirus E1A mediate two distinct mechanisms of tumor suppression. Cancer Res 2002; 62: 346-50.
48. Dickopp A, Esche H, Swart G, Seeber S, Kirch HC, Opalka B. Transformation-defective adenovirus 5 E1A mutants exhibit antioncogenic properties in human BLM melanoma cells. Cancer Gene Ther 2000; 7: 1043-50.
49. van Groningen JJ, Cornelissen IM, van Muijen GN, Bloemers HP, Swart GW. Simultaneous suppression of progression marker genes in the highly malignant human melanoma cell line BLM after transfection with die adenovirus-5 E1A gene. Biochem Biophys Res Commun 1996; 225: 808-16.
50. Samuelson AV, Narita M, Chan HM, et al. p400 is required for E1A to promote apoptosis. J Biol Chem 2005; 280: 21915-23.
51. Flinterman M, Guelen L, Ezzati-Nik S, et al. E1A activates transcription of p73 and Noxa to induce apoptosis. J Biol Chem 2005; 280: 5945-59.
52. Shao R, Hu MC, Zhou BP, et al. E1A sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of IkappaB kinases and nuclear factor kappaB activities. J Biol Chem 1999; 274: 21495-98.
53. Shao R, Tsai EM, Wei K, et al. E1A inhibition of radiation-induced NF-kappaB activity through suppression of IKK activity and IkappaB degradation, independent of Akt activation. Cancer Res 2001; 61: 7413-16.
54. Ueno NT, Bartholomeusz C, Herrmann JL, et al. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res 2000; 6: 250-59.
55. Shao R, Lee DF, Wen Y, et al. E1A sensitizes cancer cells to TRAIL-induced apoptosis through enhancement of caspase activation. Mol Cancer Res 2005; 3: 219-26.
56. Bartholomeusz C, Itamochi H, Nitta M, Saya H, Ginsberg MH, Ueno NT. Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15. Oncogene 2006; 25: 79-90.
57. Chang JY, Xia W, Shao R, Hung MC. Inhibition of intratracheal lung cancer development by systemic delivery of E1A. Oncogene 1996; 13: 1405-12.
58. Ueno NT, Bartholomeusz C, Xia W, et al. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. Cancer Res 2002; 62: 6712-16.
59. Chang JY, Xia W, Shao R, et al. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogene 1997; 14: 561-68.
60. Liao Y, Zou YY, Xia WY, Hung MC. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer. Cancer Gene Ther 2004; 11: 594-602.
61. Xing X, Liu V, Xia W, et al. Safety studies of the intraperitoneal injection of E1A-liposome complex in mice. Gene Ther 1997; 4: 238-43.
62. Xing X, Zhang S, Chang JY, et al. Safety study and characterization of E1A-liposome complex gene-delivery protocol in an ovarian cancer model. Gene Ther 1998; 5: 1538-44.
63. Yoo GH, Hung MC, Lopez-Berestein G, et al. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res 2001; 7: 1237-45.
64. Villaret D, Glisson B, Kenady D, Hanna E, Carey M, Gleich L, Yoo GH, Futran N, Hung MC, Anklesaria P, Heald AE. A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma. Head Neck 2002; 24: 661-69.
65. Hortobagyi GN, Ueno NT, Xia W, et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 2001; 19: 3422-33.
66. Madhusudan S, Tamir A, Bates N, et al. A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin Cancer Res 2004; 10: 2986-96.
67. Frisch, S.M.: US5866550 (1999).
68. Frisch, S.M.: US5776743 (1998).
69. Frisch, S.M.: US20006100243 (2000).
70. Frisch, S.M.: US20036544955 (2003).
71. Hung, M.C., Ueno, N.T.: US20067005424 (2006).
72. Hung, M.C., Chen, H., Yu, D.: US20016197754 (2001).
73. Hung, M.C., Chen, H., Yu, D.: US20016326356 (2001).
74. Hung, M.C., Chen, H., Yu, D., Paul, R.W., Loomis, A.G., LaFoc, D.N.A.: US20046683059 (2004).
75. Routes, J.M.: US20040191761A1 (2004).